Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are a woman between 18 and 75 years old
• You have been diagnosed with cervical neuroendocrine carcinoma (a specific type of cervical cancer) confirmed by a tissue or cell sample — if it is a mixed cancer type, at least 60% must be the neuroendocrine type
• Your cancer is at an early stage (FIGO Stage I or II) and a specialist doctor has assessed that surgery is possible for you
• You have at least one tumour that can be measured on a scan, meeting specific size requirements (confirm with trial site)
• You are generally well and able to carry out everyday activities with little or no limitation (confirm with trial site)
• Your doctors expect you to survive for more than 3 months after surgery
• Your blood counts are within acceptable levels — including healthy levels of red blood cells, white blood cells, and platelets (no blood transfusions in the past 14 days)
• Your liver and kidney function test results are within acceptable ranges (confirm with trial site)
• You are not currently taking part in any other clinical trial
• If you are of childbearing age, you must have a negative pregnancy blood test within 7 days before starting treatment, and you must agree to use contraception from signing the consent form until 24 weeks after the last dose
• You are willing to take part, can follow the study requirements, and agree to attend follow-up appointments

Who may not be able to join:

• You have previously had chemotherapy, radiotherapy, targeted therapy, or immunotherapy for this condition
• You are not suitable for surgery or chemotherapy due to your physical condition or organ function
• Your cancer has spread to distant parts of the body (distant metastasis)
• You have an active autoimmune disease or a history of one (such as certain types of lung, eye, bowel, liver, or heart inflammation, or thyroid conditions) — some exceptions may apply, such as vitiligo, stable thyroid replacement therapy, or controlled Type 1 diabetes (confirm with trial site)
• You have a weakened immune system, including HIV/AIDS, other immune deficiency conditions, or a history of organ or bone marrow transplant
• You have serious heart, lung, liver, or kidney disease; a neurological or mental health condition; jaundice; bowel obstruction; or a severe infection
• You are pregnant or breastfeeding
• You have a heart condition such as coronary heart disease, irregular heartbeat (including a specific abnormality on a heart trace), or reduced heart function
• Your blood clotting results are outside the acceptable range (confirm with trial site)
• You have heart failure, unstable chest pain, a heart attack within the past year, or poorly controlled heart rhythm problems
• You have a history of interstitial lung disease or non-infectious lung inflammation
• You have had an allergic reaction to Camrelizumab (the study drug) or any of its ingredients
• The research team considers you unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.